RT Journal Article
T1 Usefulness of Integrase resistance testing in proviral HIV-1 DNA in patients with Raltegravir prior failure.
A1 Fernández-Caballero, Jose Ángel
A1 Chueca, Natalia
A1 Álvarez, Marta
A1 Mérida, María Dolores
A1 López, Josefa
A1 Sánchez, José Antonio
A1 Vinuesa, David
A1 Martínez, María Ángeles
A1 Hernández, José
A1 García, Federico
K1 HIV
K1 Integrase
K1 Proviral DNA
K1 Raltegravir
K1 Dolutegravir
K1 Recuento de linfocito CD4
K1 ADN
K1 Femenino
K1 Infecciones por VIH
K1 VIH-1
K1 Compuestos heterocíclicos con 3 anillos
K1 Humanos
K1 Integrasas
K1 Mutación
K1 Proyectos piloto
K1 Provirus
K1 Raltegravir potásico
K1 Estudios retrospectivos
K1 España
K1 Carga viral
AB BACKGROUNDIn our study, we have hypothesized that proviral DNA may show the history of mutations that emerged at previous failures to a Raltegravir containing regimen, in patients who are currently undetectable and candidates to simplification to a Dolutegravir containing regimen, in order to decide on once a day or twice a day dosing.METHODSWe have performed a pilot, observational, retrospective, non interventional study, including 7 patients infected by HIV-1, all with a history of previous failure to a RAL containing regimen, that were successfully salvaged and had reached viral suppression. A genotypic viral Integrase region study was available for each patient at the moment of RAL failure. After an average (IQR) time of 48 months (29-53) Integrase resistance mutations in proviral DNA were studied.RESULTSAll the patients were infected by HIV-1 B subtypes, with a mean age of 55 (range 43 to 56), originating from Spain, and 4 were women. Median viral load (log) and CD4 count at the moment of the study on proviral DNA was of 1.3 log cp/ml (range 0-1.47) and 765.5 cells/μL (range; 436.75-1023.75). The median time (IQR) between previous failure to RAL and the study on proviral DNA was 48 (29-53) months. At Raltegravir failure, N155H was detected in four patients, and other secondary mutations were detected in five patients (71.4 %). In proviral DNA, N155H was detected by population sequencing in three patients (42.8 %), and UDS demonstrated a 9.77 % relative abundance of N155H in the remaining patient. Sanger sequencing correctly identified all the secondary mutations.CONCLUSIONThis is a pilot study that demonstrates the possibility of properly identifying N155H and some secondary mutations 29-53 months after failure.
PB BioMed Central
YR 2016
FD 2016-05-13
LK http://hdl.handle.net/10668/2382
UL http://hdl.handle.net/10668/2382
LA en
NO Fernández-Caballero JÁ, Chueca N, Álvarez M, Mérida MD, López J, Sánchez JA, et al. Usefulness of Integrase resistance testing in proviral HIV-1 DNA in patients with Raltegravir prior failure. BMC Infect Dis. 2016; 16(1):197
NO Journal Article;
DS RISalud
RD Apr 6, 2025